Cantor Fitzgerald Predicts CRVS FY2026 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Corvus Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of ($0.62) for the year. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13).

A number of other research analysts have also recently commented on the company. Wall Street Zen cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 20th. Mizuho set a $11.00 target price on shares of Corvus Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, May 20th. Oppenheimer reissued an “outperform” rating and set a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Corvus Pharmaceuticals Stock Performance

CRVS stock opened at $4.04 on Tuesday. Corvus Pharmaceuticals has a fifty-two week low of $1.75 and a fifty-two week high of $10.00. The company has a market capitalization of $275.40 million, a price-to-earnings ratio of -4.34 and a beta of 0.57. The business’s 50 day moving average price is $3.48 and its two-hundred day moving average price is $4.72.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently modified their holdings of CRVS. Geode Capital Management LLC raised its position in shares of Corvus Pharmaceuticals by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock worth $3,034,000 after purchasing an additional 3,854 shares during the last quarter. Renaissance Technologies LLC increased its stake in Corvus Pharmaceuticals by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 390,688 shares of the company’s stock valued at $2,090,000 after purchasing an additional 4,100 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in Corvus Pharmaceuticals by 24.9% in the first quarter. Oppenheimer & Co. Inc. now owns 22,534 shares of the company’s stock worth $72,000 after buying an additional 4,490 shares during the last quarter. Masso Torrence Wealth Management Inc. raised its holdings in Corvus Pharmaceuticals by 16.7% in the first quarter. Masso Torrence Wealth Management Inc. now owns 35,000 shares of the company’s stock worth $111,000 after buying an additional 5,000 shares during the last quarter. Finally, Nwam LLC lifted its stake in shares of Corvus Pharmaceuticals by 54.2% in the fourth quarter. Nwam LLC now owns 15,500 shares of the company’s stock worth $83,000 after buying an additional 5,450 shares in the last quarter. 46.64% of the stock is owned by hedge funds and other institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.